Curis Teams Up With LLS To Fund Early-Stage Research
This article was originally published in The Pink Sheet Daily
Lexington, Mass-based Curis landed up to $4 million in funding from The Leukemia & Lymphoma Society to help develop its preclinical treatment for B-cell lymphoma and multiple myeloma.
You may also be interested in...
Deals Of The Week: Will Pharmasset’s Windfall Lead To Similar Exits For Other Hepatitis C Biotechs?
Almost two weeks later, people are still talking about ramifications from Gilead’s $11 billion buyout of Pharmasset, but companies such as Roche, Elan and Curis have been active deal makers in recent days.
Geron Restructuring Sours Investors As Company Bets On Cancer
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
Curis/Genentech Report Positive Phase II Results For Vismodegib
Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.